for Good you first earnings joining afternoon. And call quarter our thank and business update.
I up we this call Chief questions. Lisa and Trevi’s will is Financial then remarks, it Delfini, on have Lisa today prepared me for Joining open some Officer.
During treat the nodularis. continued prurigo chronic we pulmonary to advance for Haduvio other our plans and first quarter, chronic idiopathic clinical for patients in IPF, indications development difficult cough or to fibrosis cough with
lead serious, of refractory anxiety. program IPF can is are morbidity to chronic pro IPF. therapies to provide the Patients and enhance IPF cough and IPF XXXX chronic with cough disease chronic mechanisms and is cause fibrotic IPF a hypothesized disease a therapy. tested and to end-of-life patient’s in update quality life. up cough hunger increased chronic Let of me air our per our an cough and cough day anti fatigue, times is to leading a chronic of also The in each cough and potentially often activation significantly impacts of major worsening. for of There on cough and that the is treatment approved programs. with no Beginning
this phase IPF cough chronic We are two our in planning of program. development parallel conduct in next to studies during
doses of milligrams doses XX placebo. Xb dose-ranging study and trial XXX The will we are first three to The that Phase and is active XX, study Haduvio BID. are planning a
to subjects be approximately a this the study timely multiple plan a and planning manner. complete are to approximately countries for in enrollment able weeks. six XXX dosing total for We We to sites in study and to conduct in of N XXX
work aware, going of there IPF is on with a may in development patients. lot antifibrotics you be As
So, we be enrollment scenario. competitive, we that for that and expect will are planning
for various study protocol the to finalized for the have regulatory are preparing and submissions dose-ranging We authorities. international
We final stages have selection. in also of are country site and CRO engaged and the our
of are study We second half this initiating year. in this the planning on
are on generic we Opioids that data studies across of depression. respiratory This causing for Xb safety not various antagonists physiology there have have impact our that the parallel, a study. a respiration. suggests date, have In seen ceiling Phase to agonist is literature effect risk planning is and something we a in our mixed respiratory on
any the respiratory population. inpatient Xb to if to population causes important the in for is pivotal see patients IPF population, given label. to levels if study respiration depression this of clinically any, ultimately, in we have that is Trevi depression. the cough of IPF with determine that will it disease our study characterize define conduct a planning drug program impairment significant However, help what we impacts patient This on degree, severity varying respiratory the are patient and Phase
the protocol finalizing We preparing submission. are the and study FDA have on the Phase feedback Xb for planned received and IND
second this expect the study initiate to half year We this well. in as of
a has brain in chronic centrally is. the underlying therapy to also the developing the of what a the works in also RCC. cough, believe for cough indication are in Phase because In addition known protocol chronic X in Haduvio Haduvio and to range preparations peripherally a refractory disease we study We cough regardless across both provide IPF the that of potential as lungs,
subjects. design, and enroll we trial was XX We look escalating expect that CANAL this to approximately a lot a dose like which will the trial, expect crossover
in in a PXXXs, peripherally which the seen has which success, some only RCC been with mechanistically of have mechanism, work There lot the trials lung. one
for opportunity the a However, peripherally we significant difficult-to-treat and most believe efficacy has works strong potential cough mechanism still both provide consistent centrally and in to and that there patients. the is a
the leveraging are learnings our work RCC development design prior the study. We companies in own from as by we other
continues at held presentations of of to garner Thoracic upcoming a date at Our at with the meeting the cough American oral conferences attention of June. Conference lot the Cough medical accepted both well as Society beginning to the data week, next American end data being as in
manuscript it finalized have for have trial a We the and submitted publication. CANAL also results on
IPF need medical across I think program and in importance to the community's indications. speaks of difficult-to-treat medical patients the this the our in cough unmet these interest
data PN, The and other nodules a or as treatment disease Prurigo the the indication where as last positive on in by and Phase year, significance The the on of Nodularis of have for primary severe characterized skin and serious key well is debilitating June is work which ongoing and trial trial we PRISM itching. papules secondary all achieved reported Xb/X the statistical endpoints. we PN. In
that study During with of first PRISM. we the the was one-year completed quarter open-label associated extension XXXX
study this After for data of with that an will analyzing and we to currently determine year. will meeting which later are from end have meeting the FDA, seek X expect We the program. we this Phase the then steps next
appropriate is currently Part to objective a conducting abuse nalbuphine two potential The by Schedule the for being against to drug. study to nalbuphine in and Agency characterize or that is this Butorphanol unscheduled Enforcement for the in or likability conducted a objective of a the IV in first the the butorphanol an comparison human X. which active with Note study of comparator, part compare is abuse filing. various parts are for The is choose oral study. butorphanol dose which parenteral doses is of the study an version oral NDA we Drug potential the this nalbuphine required Finally, for DEA. is U.S.
for completed We study. the second of selected have have and Part the X of part the study butorphanol the dose
dose placebo. into two Part to The items of butorphanol study double-blind, crossover the are nalbuphine portion selected of three to placebo-controlled of well oral a randomized, to this moving the second of as X determine abuse study. and the of gating design five-way active is as potential doses relative There
first butorphanol. shortage a The is nationwide of
to working of And study study. second, comments any are for doses the with we selection partner conduct study. results to to FDA the the to on proceeding the secure before Part Part with need of intend submit X of We from dose our the X CRO butorphanol the we
neither by of Assuming a abuse this from these two year. study line end top caused results delay, the potential of we expect items significant human the
execution get are we studies up running. closing, on and In to focused these
as studies initiated trial. and they expected provide more the details of study We lines and will the announce all-important name time design, on are the
will up for over may review it any to turn it Lisa then that you our questions will now I to we have. financial results, open
